Earnings summaries and quarterly performance for Medtronic.
Executive leadership at Medtronic.
GS
Geoffrey S. Martha
Detailed
Chief Executive Officer
CEO
BA
Brett A. Wall
Detailed
Executive Vice President and President, Neuroscience Portfolio
HS
Harry S. Kiil
Detailed
Executive Vice President and President, Cardiovascular Portfolio
MQ
Michelle Quinn
Detailed
General Counsel and Corporate Secretary
QD
Que Dallara
Detailed
Executive Vice President and President, Diabetes
TP
Thierry Piéton
Detailed
Chief Financial Officer
Board of directors at Medtronic.
CA
Craig Arnold
Detailed
Lead Independent Director
EG
Elizabeth G. Nabel, M.D.
Detailed
Director
GP
Gregory P. Lewis
Detailed
Director
JP
John P. Groetelaars
Detailed
Director
JS
Joon S. Lee, M.D.
Detailed
Director
KJ
Kendall J. Powell
Detailed
Director
KE
Kevin E. Lofton
Detailed
Director
LL
Lidia L. Fonseca
Detailed
Director
RJ
Randall J. Hogan, III
Detailed
Director
SC
Scott C. Donnelly
Detailed
Director
WR
William R. Jellison
Detailed
Director
Research analysts who have asked questions during Medtronic earnings calls.
Travis Steed
Bank of America
7 questions for MDT
Also covers: ABT, AXNX, BAX +19 more
SS
Shagun Singh Chadha
RBC Capital Markets
6 questions for MDT
Also covers: AXNX, DXCM, GMED +11 more
Vijay Kumar
Evercore ISI
6 questions for MDT
Also covers: A, ABT, AVTR +21 more
RM
Robert Marcus
JPMorgan Chase & Co.
5 questions for MDT
Also covers: ABT, BAX, BDX +21 more
Joanne Wuensch
Citigroup Inc.
4 questions for MDT
Also covers: ABT, BAX, BDX +18 more
LB
Larry Biegelsen
Wells Fargo & Company
4 questions for MDT
Also covers: ABT, ALC, AXNX +24 more
Matthew Miksic
Barclays PLC
4 questions for MDT
Also covers: ABT, ATEC, BAX +15 more
Patrick Wood
Morgan Stanley
4 questions for MDT
Also covers: ALC, BDX, BLCO +17 more
PC
Pito Chickering
Deutsche Bank
4 questions for MDT
Also covers: ACHC, AHCO, AVAH +18 more
DA
Danielle Antalffy
UBS Group AG
3 questions for MDT
Also covers: ABT, ATRC, BAX +15 more
LB
Lawrence Biegelsen
Wells Fargo
3 questions for MDT
Also covers: ABT, ALC, BAX +16 more
AP
Anthony Petrone
Mizuho Group
2 questions for MDT
Also covers: ADMA, ALC, BSX +22 more
JJ
Joshua Jennings
TD Cowen
2 questions for MDT
Also covers: ABT, ALUR, ATEC +20 more
MT
Matthew Taylor
Jefferies
2 questions for MDT
Also covers: ALUR, BDX, CQP +18 more
RM
Robbie Marcus
JPMorgan Chase & Co.
2 questions for MDT
Also covers: ABT, BAX, BDX +9 more
Christopher Pasquale
Nephron Research
1 question for MDT
Also covers: ALC, AXGN, BSX +12 more
DR
David Rescott
Baird
1 question for MDT
Also covers: HAE, INSP, IRTC +7 more
Matt Miksic
Barclays Investment Bank
1 question for MDT
Also covers: ABT, ATEC, BAX +14 more
MO
Matt O'Brien
Piper Sandler Companies
1 question for MDT
Also covers: BBNX, BSX, DXCM +6 more
Mike Kratky
Leerink Partners
1 question for MDT
Also covers: AXGN, DXCM, INSP +4 more
RN
Richard Newitter
Truist Securities
1 question for MDT
Also covers: AXNX, DXCM, GKOS +18 more
Recent press releases and 8-K filings for MDT.
Medtronic outlines four generational growth drivers and strategic priorities at JPM Healthcare Conference
MDT
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Medtronic delineated four generational growth drivers—pulsed field cardiac ablation (CAS), Symplicity renal denervation, AltaViva tibial neuromodulation, and Hugo surgical robotics—and is on track for > $2 B CAS revenue by H1 FY 27.
- The Medtronic Performance System has achieved a 5% gross COGS improvement and all-time low backorders, underpinning margin expansion and an R&D increase from ~ 8.5% to ~ 10% of revenue.
- Two new board committees—Growth and Operations—will align oversight with strategic objectives, accelerating targeted tuck-in M&A in high-growth areas while maintaining the dividend policy.
- Early U.S. rollout of Symplicity shows robust adoption with over 18 M eligible patients and coverage extending to ~ 30 M lives; Hugo’s urology launch highlights modularity, open console design, and a digital Surgery ecosystem.
2 days ago
Medtronic outlines growth drivers and Diabetes separation plan at JPM Healthcare Conference
MDT
Product Launch
New Projects/Investments
- Medtronic plans separation of its $2.8 billion Diabetes business via spin-off, split-off or offering; final structure pending.
- FY25 revenue breakdown: Cardiovascular $12.5 B, Neuroscience $9.8 B, Medical Surgical $8.4 B, Diabetes $2.8 B.
- Identified generational growth drivers in Pulsed Field Ablation, Symplicity renal denervation, Altaviva tibial neuromodulation, and Hugo surgical robotics.
- Forecasts PFA revenue doubling to $2 B in 1HFY27 (from $1 B in FY25) and launch of next-gen Symplicity Spyral in 2HFY27.
2 days ago
Medtronic outlines growth drivers and strategy at JPMorgan Healthcare Conference
MDT
Product Launch
Revenue Acceleration/Inflection
M&A
- Medtronic highlighted four “generational” growth drivers—pulsed field ablation (CAS), Symplicity renal denervation, AltaViva tibial neuromodulation, and Hugo surgical robotics—each representing >$1 billion in potential revenue; CAS is on track for $2 billion of trailing revenue by H1 FY 2027.
- The company is pursuing margin expansion via the Medtronic Performance System (5% gross cost of goods improvement) and notes that R&D growth has outpaced revenue growth in the past two quarters.
- Medtronic is simplifying its portfolio by spinning off its diabetes business via an IPO by year-end, intends to raise R&D spend to ~10% of revenue, and is ramping up tuck-in M&A through a newly formed Growth Committee.
- Early commercial traction includes 50% CAS growth in Q1 and 70% in Q2, positive reimbursement updates for Symplicity, and a purposeful Hugo urology launch to ensure strong first-user experiences.
2 days ago
Medtronic outlines four generational growth drivers at J.P. Morgan conference
MDT
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Medtronic highlighted four generational growth drivers: cardiac ablation solutions with pulsed field ablation targeting a $13 billion market and $2 billion CAS revenue by H1 FY 2027; Symplicity renal denervation with 18 million eligible U.S. patients, 1% penetration = multi-billion $/yr; AltaViva tibial neuromodulation addressing 5 million treatable UUI patients, 1% penetration = $1 billion; and Hugo robotic surgery, now FDA-cleared for urology with planned hernia and gynecology expansions.
- Operational enhancements via the Medtronic Performance System have delivered 5% gross COGS improvement and all-time low backorder levels, underpinning margin expansion goals.
- R&D spend grew faster than revenue in Q1–Q2, reaching 8.5% of sales and is targeted to increase to ~10%, prioritizing these generational opportunities, other high-growth franchises, and core cash-generating businesses.
- Capital allocation will focus on funding organic R&D, tuck-in M&A in adjacent high-growth areas, and sustaining the dividend, supported by newly formed growth and operations board committees to accelerate decision-making.
2 days ago
Medtronic announces FDA clearance for MiniMed Go Smart MDI system
MDT
Product Launch
- Medtronic received FDA 510(k) clearance for its MiniMed Go™ Smart MDI system, integrating the InPen™ smart insulin pen with Abbott’s Instinct CGM sensor in a single app.
- The system provides real-time dose calculations, missed dose alerts, actionable guidance and CareLink™ reporting to streamline multiple daily injections.
- Clearance covers individuals aged 7 years and older (and children 2–6 under adult supervision); compatibility with Medtronic’s Simplera sensor is under FDA review.
- U.S. commercial launch is expected in spring 2026.
2 days ago
Medtronic’s MiniMed unit files for US IPO
MDT
Delisting/Listing Issues
- On Dec. 19, MiniMed filed an S-1 to pursue a U.S. IPO on Nasdaq under ticker MMED, with Medtronic expected to retain about 80% of voting stock and consider a spin-off or split-off distribution.
- MiniMed generated $1.48–1.5 billion in sales and a $21 million net loss in the six months ended Oct. 24, with roughly 83% of revenue from CGMs, consumables, software and services and 70% of revenue from outside the U.S..
- The unit reported $128 million of adjusted EBITDA in the first half of fiscal 2025 and $2.7 billion in revenue for fiscal 2025, targeting an $18 billion addressable market growing at over 10% CAGR through 2030.
- Goldman Sachs, BofA Securities, Citigroup and Morgan Stanley are lead underwriters, and Medtronic’s strong parent metrics (market cap ~$126.45 billion; trailing-12 revenue ~$34.8 billion; gross margin ~65.5%) underpin the spin-off strategy.
Dec 19, 2025, 9:48 PM
Medtronic announces IPO filing for MiniMed
MDT
- Medtronic’s diabetes unit, to be named MiniMed, has filed a Form S-1 registration statement with the SEC for an initial public offering of new common stock.
- The IPO aims to list shares on the Nasdaq Global Select Market under the ticker MMED; share count and price range remain undecided.
- The separation is structured as an IPO followed by a split-off and awaits SEC review and market conditions before proceeding.
- Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley will serve as lead bookrunners, supported by several other joint managers.
Dec 19, 2025, 9:20 PM
Medtronic announces FDA clearance of Hugo RAS system for urologic procedures
MDT
Product Launch
- FDA clearance of the Hugo™ RAS system for minimally invasive urologic procedures (prostatectomy, nephrectomy, cystectomy; ~230,000 U.S. surgeries annually)
- Modular design and open surgeon console enable flexible deployment, enhanced situational awareness, and team integration; coupled with the Touch Surgery™ digital ecosystem for training, tele-proctoring, and AI-driven post-operative insights
- The Expand URO IDE study—the largest U.S. multi-port robotic urological surgery trial—met primary safety and effectiveness endpoints; globally, Hugo has been used in tens of thousands of procedures across 30+ countries
Dec 3, 2025, 9:30 PM
Medtronic launches MiniMed 780G with Abbott Instinct sensor
MDT
Product Launch
- Medtronic has initiated the broad U.S. commercial launch of its MiniMed™ 780G automated insulin delivery system integrated with Abbott’s Instinct sensor following FDA clearance, and the system is now shipping nationwide.
- The Instinct sensor, described as the world’s smallest and thinnest integrated continuous glucose monitor, offers up to 15 days of wear and provides real-time glucose readings that enable insulin adjustments every five minutes.
- Early customer pilot feedback has been reported as very positive, with users and clinicians noting improved time in range and a seamless management experience.
- This launch further expands Medtronic’s diabetes portfolio alongside the Simplera Sync™ and Guardian™ 4 sensors, reinforcing its smart dosing ecosystem and offering greater choice to patients.
Dec 2, 2025, 2:00 PM
Medtronic reports Q2 2026 earnings beat and raises guidance
MDT
Earnings
Guidance Update
Product Launch
- Medtronic delivered $9.0 billion in Q2 revenue, up 6.6% reported and 5.5% organic, and beat expectations; adjusted EPS was $1.36, up 8% year-over-year.
- The cardiac ablation PFA franchise grew 71% with a 300%+ US revenue increase, doubling the installed base of Affera mapping systems, and now represents 75% of ablation revenue.
- Received final Medicare NCD for Simplicity renal denervation, enabling broader access and reducing patient barriers; commercial payer coverage now spans 30 million lives.
- Early signs from the US launch of AltaViva for incontinence are positive, with oversubscribed physician trainings and strong consumer interest, targeting a multi-year growth driver.
- Raised fiscal 2026 revenue growth guidance to ~5.5% (up 50 bp) and EPS range to $5.62–$5.66, citing continued momentum and an FX tailwind of $625M–$725M.
Nov 18, 2025, 1:00 PM
Fintool News
In-depth analysis and coverage of Medtronic.
Quarterly earnings call transcripts for Medtronic.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more